[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639479":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":36,"responsibleParty":57,"collaborators":60,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":30,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":30,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":92,"whyStopped":30,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"University of Maryland, Baltimore","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Lebrikizumab","EXPERIMENTAL","Participants will receive subcutaneous injections of Lebrikizumab",[13],"Drug: Lebrikizumab",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Participants will receive subcutaneous injections of Lebrikizumab every two weeks for 24 weeks. The first two doses will be 500 mg, and following doses will be 250 mg.",[9],[20],"Ebglyss",[22],{"name":23,"affiliation":5,"role":24},"Kristin L Khan, MD","PRINCIPAL_INVESTIGATOR",[26,32],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Brandon J Mangracina, MA","CONTACT","732-757-5831",null,"bmangracina@som.umaryland.edu",{"name":33,"role":28,"phone":34,"phoneExt":30,"email":35},"Marie Vidaver, PhD","410-685-1726","MVidaver@som.umaryland.edu",[37],{"facility":38,"status":30,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"UM Dermatology at UM Professional Building","Baltimore","Maryland","21201","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-76.61219,39.29038,{"lat":48,"lon":47},[51,52,53,54],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},{"name":33,"role":28,"phone":34,"phoneExt":30,"email":35},{"name":23,"role":24,"phone":30,"phoneExt":30,"email":30},{"name":55,"role":56,"phone":30,"phoneExt":30,"email":30},"Carolyn Stolte, CRNP","SUB_INVESTIGATOR",{"type":24,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Kristin Khan","Assistant Professor",[61],{"name":62,"class":63},"Eli Lilly and Company","INDUSTRY","100639479","phase-2-efficacy-and-speed-of-response-of-lebrikizumab-in-high-burden-prurigo-nodularis-patients-100639479",false,"NCT07620561","Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients","Evaluating the Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients: A 24-Week Study","Inclusion Criteria:\n\n* Age 18-80\n* Diagnosis of Prurigo Nodularis (PN) for at least 1 year\n* Active PN with moderate-to-severe itch, several nodules, and presence of nodules in more than one part of the body\n* Women of childbearing potential must agree to remain abstinent or use a highly effective contraceptive method during treatment and for at least 18 weeks after the last dose of study drug\n* Male participants must agree to use an effective barrier contraceptive if sexually active with a woman of childbearing potential during treatment and for at least 18 weeks after the last dose of study drug\n\nExclusion Criteria:\n\n* Prior participation in a lebrikizumab study\n* History of anaphylaxis\n* History of or active HIV\n* Active hepatitis or known liver cirrhosis\n* History of cancer in the past 5 years, except for fully treated early cervical cancer in situ or non-melanoma skin cancers (basal cell or squamous cell skin cancer) that have been successfully treated and resolved. This includes certain skin lymphomas such as mycosis fungoides.\n* Uncontrolled chronic conditions that may require intermittent oral steroid use, such as severe uncontrolled asthma\n* Current or recent parasitic infection\n* Immunocompromised individuals\n* Pregnant or breastfeeding women or those planning to become pregnant or breastfeed during the study period\n* Use of other treatments for PN during the study, such as topical, systemic, or light-based treatments\n* Current or recent treatment with biologic drugs\n* Use of drugs that have an effect on the immune system during the study and within 4 weeks of starting the study\n* Receipt of phototherapy or light-based therapy within 4 weeks before starting the study\n* Regular use of tanning booths or parlors within 4 weeks before starting the study\n* Receipt of a live vaccine within 12 weeks before starting the study or planned receipt during the study\n* Recent use of an experimental drug\n\nOther protocol-defined Inclusion\u002FExclusion Criteria apply.","ALL","18 Years","80 Years",{"count":75,"type":76},15,"ESTIMATED","INTERVENTIONAL",[79],"PHASE2","The purpose of this study is to evaluate the effectiveness of lebrikizumab in treating adults with moderate-to-severe Prurigo Nodularis (PN).",[82],"Prurigo Nodularis (PN)",[84,85,86,87,88,89,90,91],"prurigo nodularis","prurigo","lebrikizumab","ebglyss","itch","pruritus","dermatitis","skin diseases","NOT_YET_RECRUITING","2026-05-26",{"date":95,"type":96},"2026-06-02","ACTUAL",{"date":98,"type":76},"2026-06",{"date":100,"type":76},"2028-03",{"name":5,"class":6},1]